FDA Approved: GAVRETO — Original Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved Gavreto (pralsetinib) from Genentech as an original application for treating metastatic RET fusion-positive cancers, including non-small cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Thyroid Cancer

Drugs mentioned

• GAVRETO (pralsetinib)

Snippet

ORIG AP for GAVRETO (PRALSETINIB)